EE667 Cost-Minimization Analysis (CMA) of Bruton Tyrosine Kinase Inhibitors (BTKi) in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Abstract
Authors
A. Chanan-Khan L. Mohseninejad L. Walder S. Ubi R. Gani A. Shah K. Yang